Adverum Biotechnologies, Inc. (NASDAQ:ADVM)

CAPS Rating: 3 out of 5

Caps

How do you think ADVM will perform against the market?

Add Stock to CAPS Watchlist

All Players

32 Outperform
2 Underperform
 

All-Star Players

9 Outperform
2 Underperform
 

Wall Street

0 Outperform
1 Underperform
 

Top ADVM Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

q10 (< 20)
Submitted December 20, 2017

ready to take off

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

ADVM VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about ADVM.

Recs

1
Member Avatar q10 (< 20) Submitted: 12/20/2017 10:25:24 AM : Outperform Start Price: $3.35 ADVM Score: +77.78

ready to take off

Recs

1
Member Avatar oscillation (77.00) Submitted: 8/16/2015 2:31:05 PM : Outperform Start Price: $10.50 ADVM Score: -74.02

nev

Recs

4
Member Avatar zzlangerhans (99.55) Submitted: 8/7/2014 7:56:40 PM : Outperform Start Price: $23.33 ADVM Score: -117.72

I found myself with a sudden deficit in knowledge about the recent IPO Avalanche after Portefeuille requested that I take a small position of 200 shares at 22.5 for the zzporte portfolio this week. After an hour or two of investigation into the company I had already dropped nearly five grand into, I was able to determine a few important facts.

1. The target is lucrative. Avalanche is attempting to supplant very successful drugs such as Eylea and Lucentis for the treatment of wet AMD. These are billion dollar drugs.
2. The platform is legitimate. Avalanche wants to turn the retina into a biological factory of angiogenesis inhibitors via transfection with adenoviral vectors. This is also consistent with Portefeuille's long term plan of moving the portfolio further in the direction of gene therapy.
3. The stock did well in the IPO but has been weak since then. The pipeline is early stage and speculative and there are no obvious short-term catalysts. There is little to create a floor for the share price in the near term.

Follow at your own risk.

Leaderboard

Find the members with the highest scoring picks in ADVM.

Score Leader

WalkingCaptain

WalkingCaptain (< 20) Score: +125.19

The Score Leader is the player with the highest score across all their picks in ADVM.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Bigsef77 70.75 12/19/2017 Outperform 1Y $3.25 +86.15% +2.33% +83.82 0 Comment
Momentum21 96.94 12/8/2017 Outperform 5Y $3.30 +83.33% +3.68% +79.65 0 Comment
q10 < 20 12/20/2017 Outperform 5Y $3.35 +80.60% +2.81% +77.78 1 Comment
slnoutperform 38.56 1/2/2018 Outperform 5Y $3.65 +65.75% +2.58% +63.18 0 Comment
stainsolution 47.30 1/2/2018 Outperform 5Y $3.65 +65.75% +2.58% +63.18 0 Comment
Jordrok 89.38 2/13/2018 Underperform 1Y $6.75 -10.37% +4.08% +14.45 0 Comment
aleksandrk 40.96 5/6/2016 Outperform 5Y $4.46 +35.65% +34.13% +1.52 0 Comment
vectorplexus 33.45 4/10/2018 Outperform 5Y $5.98 +1.26% +4.02% -2.77 0 Comment
IgnorantAmateur 61.58 1/26/2018 Outperform 1Y $6.83 -11.36% -3.51% -7.84 0 Comment
Plasmidologist 32.66 1/29/2018 Outperform 5Y $7.50 -19.33% -3.48% -15.86 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJimCramer 85.44 3/23/2015 Underperform 3W $43.07 -85.95% +30.83% +116.78 0 Comment

Featured Broker Partners


Advertisement